Elsa Ávila Arreguin

The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy

Efficient site-specific integration of large genes in mammalian cells via continuously evolved recombinases and prime editing

Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial

A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1